SHANGHAI and SAN FRANCISCO, and CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and the recent pandemic-related restrictions in Shanghai, the format of the extraordinary general meeting of shareholders (EGM) of Zai Lab Limited has been changed and will be held in a virtual meeting format only. The purpose of the EGM is to consider and vote on a proposal relating to a proposed 1-to-10 share subdivision of the ordinary shares of Zai Lab Limited. As previously announced, the EGM will be held on March 28, 2022 at 8:00 a.m. (U.S. Eastern Time) / 8:00 p.m. (Hong Kong Time).
Shareholders of record of our ordinary shares as of the relevant record date may attend the EGM virtually by visiting our EGM website at�www.virtualshareholdermeeting.com/ZLAB2022SM. Shareholders will need the�16-digit�control number included on their proxy card or on the instructions that accompanied their proxy materials. Shareholders are encouraged to log in to this website and�pre-register�for the EGM before the start time of the meeting. Online�check-in�will begin 15 minutes prior to the start of the meeting, and shareholders should allow ample time for the online�check-in�procedures. The proxy materials previously distributed will not be updated to reflect the change in format, but may continue to be used to vote your shares in connection with the EGM.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing, and commercializing our portfolio in order to impact human health worldwide.
For additional information about Zai Lab, please visit www.zailaboratory.com�or follow us at www.twitter.com/ZaiLab_Global.
For more information, please contact:
Investor Relations: Ron Aldridge / Lina Zhang
+1 (781) 434-8465 / +86 136 8257 6943
[email protected]�/[email protected]
Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
[email protected]�/ [email protected]
Source: Zai Lab Limited
